Why the study?
Cardiac sarcoidosis and giant cell myocarditis share histopathologic and clinical features, raising the question of whether they represent parts of a one-disease continuum.
Does giant cell myocarditis have a worse prognosis compared to cardiac sarcoidosis?
Population
351 CS and 28 GCM cases diagnosed in Finland
Comparison
Cardiac sarcoidosis vs giant cell myocarditis
Design
Nationwide cohort study
Follow-up
Followed until February 2018
Authors
Loading...
GCM associated with higher cardiac event risk than CS; leaves open whether histopathology independently predicts outcomes beyond myocardial injury extent.
Does giant cell myocarditis have a worse prognosis compared to cardiac sarcoidosis?
Giant cell myocarditis presents with more extensive myocardial injury and worse long-term outcomes than cardiac sarcoidosis, though prognosis is primarily driven by the extent of myocardial injury rather than the specific histopathologic diagnosis.
Nordenswan et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: